Dr Reddys Laboratories (RDY) EBITDA Margin (2009 - 2026)

Dr Reddys Laboratories has reported EBITDA Margin for 18 years, with the latest figure at 4.69% in Q2 2026.

• On a quarterly basis, EBITDA Margin fell 1576.0% year-over-year to 4.69% in Q2 2026; TTM through Jun 2026 was 11.33%, a 1004.0% decrease from a year earlier, with the FY2026 full-year figure at 16.0%, down 586.0% from the prior year.
• EBITDA Margin was 4.69% for Q2 2026 at Dr Reddys Laboratories, up from 1.76% in the prior quarter.
• The five-year high for EBITDA Margin was 26.14% in Q1 2023, with the low at 1.76% in Q1 2026.
• Average EBITDA Margin over 5 years is 19.16%, with a median of 21.51% recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: EBITDA Margin jumped 2335 bps in 2023, then sank 1898 bps in 2026.
• Over 5 years, EBITDA Margin stood at 19.69% in 2022, then rose by 22 bps to 23.93% in 2023, then slipped by 6 bps to 22.4% in 2024, then dropped by 27 bps to 16.32% in 2025, then plunged by 71 bps to 4.69% in 2026.
• The last three EBITDA Margin figures came in at 4.69% (Q2 2026), 1.76% (Q1 2026), and 16.32% (Q4 2025), per Business Quant data.